Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration.

Human mutation - 1 Jan 2026

Jiang Yiqing, Wang Na, Zeng Qin, Liu Jun, Liu Xiaoqin, Cao Guili

Abstract excerpt

Immune checkpoint inhibitors have become integral to the management of non-small cell lung cancer (NSCLC), yet both primary and acquired resistance remain frequent and are only partially captured by routine biomarkers such as programmed death-ligand 1 (PD-L1) immunohistochemistry and tumor mutational burden (TMB). Resistance is increasingly viewed as a multiaxis functional phenotype shaped by antigenicity and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genomics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Multiomics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 42181742
DOI: 10.1155/humu/6434376
PMCID: PMC13191777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration.PMID 42181742Read ↗

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug ResistanceSemantic proximity Read ↗

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read ↗

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read ↗

Bridging Discovery and Treatment: Cancer BiomarkerSemantic proximity Read ↗

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity Read ↗

Coordinated Multicellular Immune Programs and Drug Targets Revealed by Single-Cell Analysis in Driver-Mutated NSCLC.Semantic proximity Read ↗

Towards Precision Oncology: How Advances in Cancer Genomics, Immunobiology and Artificial Intelligence Will Change Molecular DiagnosticsSemantic proximity Read ↗

Pan-Cancer Biomarker Analysis from the Cancer Dependency Map: A Blueprint for Precision OncologySemantic proximity Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.Semantic proximity Read ↗

Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.